Merus N.V. (MRUS): Price and Financial Metrics


Merus N.V. (MRUS): $14.97

-0.20 (-1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MRUS POWR Grades

  • MRUS scores best on the Value dimension, with a Value rank ahead of 67.47% of US stocks.
  • The strongest trend for MRUS is in Growth, which has been heading down over the past 179 days.
  • MRUS ranks lowest in Growth; there it ranks in the 3rd percentile.

MRUS Stock Summary

  • Of note is the ratio of MERUS NV's sales and general administrative expense to its total operating expenses; just 12.28% of US stocks have a lower such ratio.
  • MRUS's price/sales ratio is 15.44; that's higher than the P/S ratio of 93.19% of US stocks.
  • With a year-over-year growth in debt of 216.42%, MERUS NV's debt growth rate surpasses 93.47% of about US stocks.
  • Stocks that are quantitatively similar to MRUS, based on their financial statements, market capitalization, and price volatility, are TSVT, RARE, AGIO, XENE, and EDIT.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to www.merus.nl.

MRUS Valuation Summary

  • In comparison to the median Healthcare stock, MRUS's price/earnings ratio is 150% lower, now standing at -11.6.
  • Over the past 79 months, MRUS's EV/EBIT ratio has gone down 4.4.

Below are key valuation metrics over time for MRUS.

Stock Date P/S P/B P/E EV/EBIT
MRUS 2022-11-25 16.1 2.5 -11.6 -8.7
MRUS 2022-11-23 15.8 2.4 -11.3 -8.4
MRUS 2022-11-22 16.2 2.5 -11.6 -8.7
MRUS 2022-11-21 16.7 2.5 -11.9 -9.1
MRUS 2022-11-18 16.6 2.5 -11.9 -9.0
MRUS 2022-11-17 17.3 2.6 -12.4 -9.5

MRUS Growth Metrics

    Its year over year price growth rate is now at -17.05%.
  • Its year over year revenue growth rate is now at 63.83%.
  • Its 4 year revenue growth rate is now at 868.33%.
MRUS's revenue has moved up $14,496,000 over the prior 33 months.

The table below shows MRUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 45.629 -150.985 -63.643
2022-06-30 52.717 -132.804 -53.881
2022-03-31 52.412 -125.367 -75.555
2021-12-31 49.107 -59.627 -66.816
2021-09-30 43.414 -52.365 -80.359
2021-06-30 38.315 -40.987 -88.581

MRUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRUS has a Quality Grade of D, ranking ahead of 21.68% of graded US stocks.
  • MRUS's asset turnover comes in at 0.127 -- ranking 244th of 682 Pharmaceutical Products stocks.
  • ACUR, ABBV, and KMPH are the stocks whose asset turnover ratios are most correlated with MRUS.

The table below shows MRUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.127 1 -1.828
2021-06-30 0.125 1 -4.520
2021-03-31 0.120 1 -2.933
2020-12-31 0.132 1 -2.684
2020-09-30 0.122 1 -2.459
2020-06-30 0.124 1 -1.944

MRUS Price Target

For more insight on analysts targets of MRUS, see our MRUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.71 Average Broker Recommendation 1.25 (Strong Buy)

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $14.97 52-week high $33.09
Prev. close $15.17 52-week low $12.03
Day low $14.51 Volume 445,300
Day high $15.01 Avg. volume 278,074
50-day MA $19.17 Dividend yield N/A
200-day MA $22.34 Market Cap 693.16M

Merus N.V. (MRUS) Company Bio


Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.


MRUS Latest News Stream


Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream


Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about MERUS NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET. The webcast of the presentation will be contemporaneous

Yahoo | November 9, 2022

Merus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Merus ( NASDAQ:MRUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.58m (down 52% from 3Q 2021). Net...

Yahoo | November 9, 2022

Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Merus Announces Financial Results for the Third Quarter and Provides Business Update

– Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics– Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potential BLA filing– Clinical update of petosemtamab planned for first half of 2023 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company

Yahoo | November 3, 2022

Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

- MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels​ - Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enrolling - Investor call to discuss a MCLA-129 program update on October 26 at 13:30 CET/7:30am ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we

Yahoo | October 26, 2022

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo -2.03%
3-mo -37.42%
6-mo -29.95%
1-year -39.32%
3-year -11.84%
5-year -4.10%
YTD -52.92%
2021 81.40%
2020 24.50%
2019 0.57%
2018 -27.84%
2017 -8.10%

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7918 seconds.